Association of iron infusion reactions with ABO blood type

Autor: Ayesha Butt, Tinatin Muradashvili, Sara Soliman, Fangyong Li, Adrienne J. Burns, Andrea Brooks, Sabrina Browning, Noffar Bar, Gena Borgman, George Goshua, John Hwa, Kelsey Martin, Henry Rinder, Christopher Tormey, Alexander B. Pine, Robert D. Bona, Alfred I. Lee, Natalia Neparidze
Rok vydání: 2022
Předmět:
Zdroj: European Journal of Haematology. 109:519-525
ISSN: 1600-0609
0902-4441
DOI: 10.1111/ejh.13838
Popis: We sought to determine risk factors for iv iron infusion-related reactions (IRR), and identify strategies for iron repletion after IRR.We conducted a retrospective chart review of patients treated in the classical hematology clinic at Yale Cancer Center (n = 330 consecutive patients) from 2016 to 2021, who received iv ferumoxytol (60.3%), iron sucrose (14.8%), or iron dextran (10.9%).The iv iron IRR was noted in 58 (17.6%) patients, 62.1% of whom had previously tolerated iv iron. The severity of IRR was mild in 22, moderate in 23, and severe in 11 patients. Most (72.4%) patients who experienced IRR tolerated a subsequent iv iron infusion. On multivariable analysis, a history of non-medication allergies was associated with greater odds of IRR (odds ratio [OR] 2.12, 95% confidence interval (CI): 1.16-3.87, p = .01). No patients with type AB blood, and few with type A blood (n = 6), had IRR; compared to type A or AB together, patients with type B (OR 5.00, 95% CI: 1.56-16.06, p = .007) or type O (OR 3.71, 95% CI: 1.44-9.55, p = .007) blood had greater odds of IRR.This study highlights a possible association of blood type with iv iron IRR; prospective studies with larger patient numbers are warranted to explore this association.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje